IntelliPlex™ Lung Cancer Panel - cfRNA

The IntelliPlex™ Lung Cancer Panel comprises NSCLC driver genes' DNA mutations and RNA fusion variants detection for use with samples extracted from NSCLC formalin-fixed paraffin-embedded tissues (FFPET) or liquid biopsies such as plasma.
The cfRNA panel is a qualitative molecular assay for the detection of 28 RNA variant hotspots in ALK, ROS1, RET, NTRK1, and MET genes from plasma samples in a single well by using PlexBio's core πCode™ technology.

FEATURES

Detect 5 driver genes, 28 RNA fusion variants in one well test
Highly sensitive (10~89 copies) to detect low levels of RNA variants
Only ≥50ng RNA sample required
Time to results in <6 hours for 96 samples per run (sample preparation included)

DOWNLOAD FILE

Broad Target Coverage

Detectable 5 driver genes,
28 RNA variants in one well

Low Sample Input

Only ≥50ng RNA sample extracted from plasma required

High Sensitivity

Detects low levels of RNA variants with a high sensitivity

Quick Turnaround Time

Sample to results in <6 hours with automated reporting

Overview

Related Products

Overview

While most lung cancer cases are sporadic rather than inherited, certain genes and even specific types of mutations are frequently observed in these cases. Traditional methods to identify certain mutations often rely on single-gene testing, which can be costly, time-consuming, and challenging due to the limited availability of clinical samples. The need for multiple, sequential tests increases the risk of insufficient sample volume, making it difficult to obtain a comprehensive molecular profile.

To address these limitations, the IntelliPlex™ Lung Cancer Panel- cfRNA is an in-vitro molecular test based on πCode™technology and PlexBio's instrument platform to identify 28 RNA fusion variants in ALK, ROS1, RET, NTRK1, and MET genes in NSCLC. πCode™ technology enables the multi-variants detection in single-well with RNA samples derived from plasma. The kit provides all necessary optimized reagents for the sensitive detection of low levels of RNA variants in a background of wild-type genomic RNA by one-step RT-PCR and simultaneous PCR amplification of target cDNA to evaluate genetic status.

Principle of πCode Multiplexing

BACK TO LIST